According to Supernus Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 38.1266. At the end of 2022 the company had a P/E ratio of 31.6.
Year | P/E ratio | Change |
---|---|---|
2022 | 31.6 | 10.42% |
2021 | 28.6 | 173.84% |
2020 | 10.4 | -5.37% |
2019 | 11.0 | -28.93% |
2018 | 15.5 | -55.98% |
2017 | 35.3 | 156.98% |
2016 | 13.7 | -70.39% |
2015 | 46.3 | -245.18% |
2014 | -31.9 | 1136.28% |
2013 | -2.58 | -24.59% |
2012 | -3.42 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 10.4 | -72.79% | ๐บ๐ธ USA |
Abbott Laboratories ABT | 36.2 | -5.13% | ๐บ๐ธ USA |
Eli Lilly LLY | 135 | 253.89% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 11.3 | -70.35% | ๐บ๐ธ USA |
Zogenix ZGNX | -6.56 | -117.19% | ๐บ๐ธ USA |
United Therapeutics UTHR | 12.1 | -68.25% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.